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Predictors of protectionIn the absence of biomarkers of protective immunity, newly developed vaccines against bovine tubercu-
losis need to be evaluated in virulent Mycobacterium bovis challenge experiments, which require the use
of expensive and highly in demand Biological Safety Level 3 (BSL3) animal facilities. The recently devel-
oped bovine BCG challenge model offers a cheaper and faster way to test new vaccine candidates and
additionally reduces the severity of the challenge compared to virulent M. bovis challenge in line with
the remits of the NC3Rs. In this work we sought to establish the sensitivity of the BCG challenge model
by testing a prime boost vaccine regimen that previously increased protection over BCG alone against M.
bovis challenge. All animals, except the control group, were vaccinated subcutaneously with BCG Danish,
and half of those were then boosted with a recombinant adenoviral vector expressing Antigen 85A,
Ad85A. All animals were challenged with BCG Tokyo into the prescapular lymph node and the bacterial
load within the lymph nodes was established. All vaccinated animals, independent of the vaccination reg-
imen, cleared BCG significantly faster from the lymph node than control animals, suggesting a protective
effect. There was however, no difference between the BCG and the BCG-Ad85A regimens. Additionally, we
analysed humoral and cellular immune responses taken prior to challenge for possible predictors of pro-
tection. Cultured ELISpot identified significantly higher IFN-ɣ responses in protected vaccinated animals,
relative to controls, but not in unprotected vaccinated animals. Furthermore, a trend for protected ani-
mals to produce more IFN-ɣ by quantitative PCR and intracellular staining was observed. Thus, this model
can also be an attractive alternative to M. bovis challenge models for the discovery of protective
biomarkers.
 2019 Published by Elsevier Ltd.1. Introduction
Mycobacterium bovis is an intracellular bacterium that predom-
inantly causes tuberculosis in cows (bTB), but can also infect
humans [1,2]. Human tuberculosis caused byM. bovis is recognised
by the WHO as one of several neglected zoonotic diseases, mainly
affecting low and middle income countries [3,4]. In the UK, bTB
causes animal welfare and productivity issues to the farming
industry with a cost to the government of approximately £100 mil-
lion a year [5]. Currently, there is no vaccine licensed for use in cat-
tle. Experimentally, however, Bacillus Calmette-Guérin (BCG), a
live attenuated M. bovis strain that is routinely used to vaccinatehumans against Mycobacterium tuberculosis, has shown to confer
partial protection in cattle, similar to humans [6–8]. A more effica-
cious vaccine along with current control measures could help to
eradicate bTB from the UK [9] and reduce the burden of bTB in
countries in which other control measures, such as test and slaugh-
ter, are not used due to cost or societal reasons. Vaccine develop-
ment, however, is hindered by the lack of biomarkers of
protective immunity. Therefore, vaccine candidates have to be
tested in expensive and lengthy pathogenic M. bovis challenge
experiments which require BSL3 facilities which are not widely
available (Table 1). Methodologies which allow for an easier, faster
and cheaper way to evaluate the efficacy of newly developed vac-
cine candidates are urgently needed. We recently developed a
bovine BCG challenge model that has the potential to be used as
a gating system to preselect vaccine candidates [10]. In the BCG
challenge model, animals are challenged into the prescapularvaccine
Table 1
Comparison of experimental parameters of the M. bovis challenge and BCG challenge
model. BSL3 requires animals to be housed in high containment facilities which are in
high demand and very expensive, in contrast to less stringent requirements for BSL2
facilities.
M. bovis challenge BCG challenge
Biological safety
level (BSL)
BSL 3 BSL 2
Duration of experiment 28 weeks 15 weeks
Challenge in vivo
endobronchial
virulent M. bovis
in vivo
intranodal
non virulent BCG
Protection read out Total pathology
Histopathology
Bacterial burden in
lung and lymph nodes
(CFU counts)
Bacterial burden in
lymph node (CFU counts)
2 L. Biffar et al. / Vaccine xxx (xxxx) xxxlymph node with a non-virulent BCG Tokyo strain, obviating the
need for expensive BSL3 containment facilities and reducing the
challenge phase from over six to three weeks. Protected animals
exhibit an immune response capable of rapid removal of mycobac-
teria from the lymph node, whereas unprotected animals are less
able to control BCG replication. The number of BCG bacilli in the
lymph nodes of protected animals is therefore expected to be
lower than in lymph nodes of unprotected animals. Only vaccines
providing protection greater than that conferred by BCG in the BCG
challenge model would have to be tested in M. bovis challenge
experiments, which would reduce the amount of animals chal-
lenged with virulentM. bovis. The BCG challenge model thus repre-
sents both refinement and reduction to the currently used M. bovis
challenge model (Table 1), consistent with the principles of the 3Rs
in research using animals [11]. The aim of this work was to evalu-
ate the sensitivity of the BCG challenge model by testing its ability
to differentiate between different vaccine regimens. To do so we
tested a previously developed heterologous prime boost vaccine
regimen, where animals were initially vaccinated with BCG and
then boosted with a recombinant adenovirus type 5 expressing
Ag85A (Ad85A) [12,13]. This vaccination regimen significantly
increased protection over that of BCG vaccination alone based on
histopathological evaluation of numbers and severity of granulo-
mas [14]. Furthermore, we were interested to determine whether
the BCG challenge model would confirm previously identified pre-
dictors of protection in M. bovis challenge experiments such as
antigen specific T cell memory response and antigen specific gene
expression in peripheral blood mononuclear cells (PBMC). We
additionally analysed IgG titres in ex vivo serum and T cell memory
response before and after challenge in effector CD45RO+CD62Llo
and central memory cells CD45RO+CD62Lhi as potential novel pre-
dictors of protection.2. Material and methods
2.1. Animals and experimental set up
Experiments were carried out according to the UK Animal (Sci-
entific Procedures) Act 1986 under project license PPL70/7737. The
study protocol was approved by the APHA Animal Use Ethics Com-
mittee (UK Home Office PCD number 70/6905). Thirty six Holstein-
Friesian crosses of between 6 and 10 months of age were sourced
from an officially bovine TB free herd. Animals were selected based
on their lack of in vitro IFN-ɣ response toM. avium purified protein
derivative (PPD-A) or to PPD from M. bovis (PPD-B). Cattle were
randomly divided into two groups of 14 animals each – BCG and
BCG-Ad85A group respectively – and one group of 8 animals – con-
trol group. At week 12 one animal of the BCG group developedPlease cite this article as: L. Biffar, L. Blunt, W. Atkins et al., Evaluating the sensit
regimen, Vaccine, https://doi.org/10.1016/j.vaccine.2019.11.005pneumonia and had to be culled with no other animal of any of
the groups being affected.
2.2. Mycobacteria
BCG SSI, for vaccination, and BCG Tokyo, for challenge, were
grown to mid-log phase in 7H9 medium supplemented with OADC
and 0.05% Tween 80 and frozen in aliquots at 80 C until used.
Mycobacteria were thawed and diluted or concentrated to the
appropriate density in 7H9 medium (see below).
2.3. Vaccination, boost and challenge
Fig. 1 depicts the experimental schedule starting with week
zero, when animals of the BCG and BCG-Ad85A group were vacci-
nated subcutaneously into the left prescapular area of the neck
with 2  106 colony forming units (CFU) BCG SSI Danish 1331.
Eight weeks later animals of the BCG-Ad85A group received an
intradermal booster of 109 plaque forming units (PFU) Ad85A
[15]. At week 12 all animals were challenged intranodally with
2  107 CFU BCG Tokyo into the left and right prescapular lymph
node. Three weeks later cattle were euthanized (week 15) and
the prescapular, submandibular and popliteal lymph nodes were
harvested. Detailed description of intranodal challenge, including
a video, can be found in Villarreal-Ramos et al. [10].
2.4. Post mortem examination and bacterial culture
As previously described lymph nodes were cleared from liga-
ments and fat, dipped in 70% EtOH, cut into small pieces and then
macerated with 7 ml HBSS in a stomacher (Seward) for 2 min. The
macerate was stored in 1 ml aliquots at 80C. For each animal a
1 ml aliquot was thawed and a 10 fold serial dilution in 7H9 media
was prepared from the macerates and plated on modified 7H11
Agar plates. In addition, bacterial load was determined using the
liquid culture BD BACTECTM MGITTM system. For that, 1 ml of macer-
ate was decontaminated using the BD BBLTM MycoPrepTM system
before 500 ml of ten times diluted macerate were added to the
BD BACTECTM MGITTM mycobacterial growth indicator tubes. Colony
counts, obtained after incubating plates for 6 weeks at 37C, were
then compared to time to positivity (TTP), the read out of the BAC-
TEC liquid culture.
2.5. Sampling and PBMC isolation
Whole blood was collected from the jugular vein at weeks 0, 4, 6
and 8 before boost and then every week after boost (Fig. 1) and
PBMC were isolated as follows. Heparinised whole blood was
diluted 1 in 2 with HBSS buffer (Gibco Life Technologies, UK) and
30 ml of the dilution was overlaid on 15 ml histopaque-1077
(Sigma, UK) in a 50 ml falcon tube and centrifuged for 45 min at
800g with no break. Using a 3 ml pastette the cell interphase was
collected and washed twice in HBSS before cells were frozen in
FCS containing 10% DMSO and stored in liquid nitrogen until fur-
ther use.
2.6. Whole blood IFN-ɣ ELISA
At the time points described above, triplicates of whole blood,
250 ml each, were incubated with antigens or media only (negative
control); bovine tuberculin purified protein derivative (PPD-B) 1 in
100 final dilution from the stock solution provided by the manu-
facturer (Prionics, Switzerland); recombinant Ag85A 5 mg/ml final
concentration (Lionex, Germany); BCG Tokyo 106 CFU/ml final con-
centration; poke weed mitogen (PWM, positive control) 10 mg/ml
final concentration (Sigma, UK) at 37 C and 5% CO2. After 16 hivity of the bovine BCG challenge model using a prime boost Ad85A vaccine
Fig. 1. Experimental schedule. Out of 36 animals, 28 were vaccinated with BCG Danish at week 0 (BCG only). 8 weeks later 14 of the vaccinated animals were boosted with
Ad85A (BCG-Ad85A) and 12 weeks after initial vaccination all animals of the three groups (control, BCG only and BCG-Ad85A) were challenged intranodally with BCG Tokyo.
One animal of the BCG only group had to be euthanised due to an unrelated pneuomonia infection. At week 15, animals were euthanised and prescapular, submandibular and
popliteal lymph nodes were harvested (post mortem). Blood samples were collected at all time points indicated and always before further treatment was performed.
L. Biffar et al. / Vaccine xxx (xxxx) xxx 3100 ml supernatant was harvested from each well and stored at
20 C. Once samples of all weeks had been collected IFN-ɣ
expression was measured using a BOVIGAMTM TB Kit (Prionics,
Switzerland) as per manufacturer’s instructions.
2.7. Cultured elispot
Cultured Elispot was carried out as described previously with
the following modifications [12]. Cryopreserved PBMC collected
at week 10 were stimulated with recombinant Ag85A at 5 mg/ml
for 13 days. On day 13 all cells were washed and resuspended in
cell culture medium (RPMI 1640 containing 2 mM GlutaMax,
25 mM HEPES, 0.1 mM NEAA, 5  10–5 M b-mercaptoethanol,
100 U/ml penicillin, 100 mg/ml streptomycin (all from Gibco Life
Technologies, UK)). Additionally, freshly isolated autologous
CD14+ cells were used as antigen presenting cells (APC) and plated
out at 2  103 APC/well on a pre-coated ELISPOT plate. CD14 + cells
were isolated using magentic beads coated with an antibody to
human CD14 that crossreacts with bovine CD14 cells (MACS, Mil-
tenyi Biotec, UK). 2  104 PBMC were added to each well and the
cell mix was stimulated with either PPD-B (10 mg/ml), Ag85A
(5 mg/ml), PWM (10 mg/ml) or RPMI for 24 h. Staining and calcula-
tion of spot forming units was performed as previously described
[12].
2.8. Real time PCR
To measure antigen specific gene expression 2  106 PBMC
were stimulated overnight (o/n) with PPD-B (10 mg/ml), Ag85A
(5 mg/ml) or media. PBMC were then lysed in lysis buffer contain-
ing TCEP (Qiagen) and kept at 80 C until further use. RNA of
PBMC was extracted using the Qiagen RNeasy Minikit according
to manufacturer’s protocol and RNA quantity was measured using
a NanoDropTM 1000 spectrometer (Thermo Fisher, UK). RNA was
transcribed into cDNA using the InvitrogenTM SuperScriptTM VILOTM
kit (Sigma) and qPCR was performed using TaqMan Assay
(Thermo Fisher Scientific). Gene expression is presented as fold
change, calculated using the 2DDCT method [16] and normalised
against the geometrical mean of three reference genes (GAPDH,
SDHA and YWAHZ).
2.9. IgG ELISA
We optimised the evaluation of mycobacterial specific IgG by
ELISA as follows. 96 well polysorp plates (Nunc-ImmunoTM Micro-
WellTM 96 well solid plates) were coated with 100 ml of 10 mg/ml
PPD-B or 1 mg/ml Ag85A in 0.1 M NaHCO3 and incubated o/n at
4 C. The following day wells were washed three times with
200 ml PBS contaning 0.1% Tween20 (PBTween) and then incubated
with 200 ml blocking buffer consisting of PBS and 3% bovine serum
albumin (BSA, SIGMA, UK) for one hour at room temperature (RT).
Subsequently, blocking buffer was discarded and serum samples
were diluted 1 in 50 in blocking buffer and incubated for one hour
at RT. After four washes with PBTween, 100 ml of mouse antibodyPlease cite this article as: L. Biffar, L. Blunt, W. Atkins et al., Evaluating the sensit
regimen, Vaccine, https://doi.org/10.1016/j.vaccine.2019.11.005to bovine IgG conjugated to horse radish peroxidase (IgG-HRP) at
a concentration of 1 mg/ml using PPD-B and 0.25 mg/ml using
Ag85A as the coating antigen- (clone IL-A2, MCA2439P, BioRad,
UK) was added to the wells and plates were incubated for 1 h at
RT, followed by four washes with PBTween. Finally 100 ml TMB
substrate (Sigma-Aldrich, UK) was added to the wells and the ELISA
was developed for 10 min at RT. The addition of 50 ml 1 M sulphuric
acid to each well stopped the reaction and the plate was read at
450 nm absorbance.2.10. PBMC culture and intracellular flow staining
Frozen PBMC were thawed, resuspended in tissue culture med-
ium (TCM, RPMI 1640 containing 2 mM GlutaMax, 25 mM HEPES,
0.1 mM NEAA, 5  10–5 M b -mercaptoethanol, 100 U/ml peni-
cillin, 100 lg/ml streptomycin [all from Gibco Life Technologies,
UK] and 10% fetal calf serum [Sigma-Aldrich, UK]) and incubated
for 2 h at 37 C in an atmosphere of 95% humidity and 5% CO2
(all following incubation steps were performed under the same
conditions). Subsequently cells were diluted in TCM at a concentra-
tion of 2  106/ml and transferred to a 12 well plate (2 ml/well). To
analyse antigen specific memory response, cells were cultured for
6 h with 2 ml of TCM containing either PPD-B (1 in 100), PWM
(10 mg/ml) or TCM only in the presence of 10 mg/ml Brefeldin A
(Biolegend, UK). After 16 h culture, cells were washed and resus-
pended in FACS buffer (HBBS containing 0.5% BSA and sodium
azide) and stained for cell surface markers either with a primary
antibody followed by a secondary fluorescently labelled antibody
– CD45RO (IL-A116, IgG3) followed by rat anti mouse IgG3-
BV421 (Biolegend, UK), CD62L (CC32, IgG1) followed by rat anti
mouse IgG1-PerCP/Cy5.5 (Biolegend, UK and ɣd (GB21A, IgG2b,
Kingfisher) followed by goat anti mouse IgG2b-PE-Cy7 (Abcam,
UK) – or with a directly labelled antibody – CD4-APC/FireTM 750
(custom conjugated Biolegend, UK), CD8-AF647 (BioRad, UK).
Additionally, cells were stained with Zombie AquaTM (Biolegend,
UK) to discriminate live from dead cells. For intracellular staining
(ICS), cells were treated with Cytofix/Cytoperm (BD Biosciences,
UK) according to manufacturer’s instruction. Cells were then incu-
bated with an antibody to IL-2 [17] followed by staining with a sec-
ondary polyclonal goat anti-human IgG F(ab0)2-FITC (BioRad, UK)
and anti-bovine IFN-ɣ-PE antibody (clone CC302, BioRad, UK). A
mix of single stained beads and single stained cells, unstimulated
samples and FMO controls were used as controls and to calculate
compensation. Up to 600,000 total events per sample were
acquired on a LSRFortessaTM analyser (BD) and the data was anal-
ysed using FlowJo software (version 10, Tree Star Inc.). An exam-
ple of the gating strategy used is provided in supplementary
material Fig. 1.2.11. Statistics
Statistical analysis of data and preparation of graphs was per-
formed using GraphPad Prism7. If not mentioned otherwise oneivity of the bovine BCG challenge model using a prime boost Ad85A vaccine
4 L. Biffar et al. / Vaccine xxx (xxxx) xxxor two-way ANOVA with Tukey’s multiple comparison test was
performed on datasets.
3. Results
3.1. Vaccination, boost and challenge induce antigen specific immune
responses
To demonstrate an immunogenic effect of vaccination, boost
and challenge, antigen specific IFN-ɣ expression in whole blood
induced by o/n stimulation with either bovine PPD-B, or Ag85A
was analysed, using a commercially available ELISA (BOVIGAM,
Prionics). PPD-B specific IFN-ɣ expression in whole blood was mea-
sured at week 0 (prior to vaccination), 4, 6 and 8 after vaccination,
and every week after boost (week 9 to week 15, Fig. 2A). No anti-
gen specific IFN-ɣ was detected in any animal of the three groups
prior to vaccination. Four weeks later IFN-ɣ expression had
increased significantly in both vaccinated groups compared to
the control group (BCG-Ad85A P < 0.0001; BCG P = 0.005). At week
six IFN-ɣ expression decreased, followed by a slight increase at
week eight. Boosting animals of the BCG-Ad85A group with
Ad85A at week 8 resulted in increased IFN-ɣ expression in this
group at week 9 (P = 0.002). One week later (week 10) expression
levels declined to the same level as seen in the BCG only group.
After challenge (week 13) IFN-ɣ expression increased significantly
in both vaccinated groups compared to the control group
(P < 0.0001) and in the control group compared to week 12
(P = 0.0004), followed by a decline in vaccinates and boosted ani-
mals one week later but not in control animals. To determine the
effect of the intradermal boost, Ag85A specific IFN-ɣ expressionFig. 2. Antigen specific immune response induced by vaccination, boost and challenge
supernatant was harvested and IFN-ɣ expression analysed using a commercial ELISA (Bo
subtraction of media only control (A and B). Additionally, occurrence of antigen specific I
n = 8 (s), BCG only vaccinates n = 13 ( ), Ad85A boosted animals n = 14 ( ). Two-way-A
at week 4 ****P < 0.0001, **P = 0.005 respectively and week 13 ****P < 0.0001; Controls ve
***P = 0.0004 (A); BCG-Ad85A versus control group at week 9 *P = 0.03; BCG and BCG-A
Controls versus BCG-Ad85A and BCG only at week 14 **P < 0.01 (C); BCG-Ad85A versus
Please cite this article as: L. Biffar, L. Blunt, W. Atkins et al., Evaluating the sensit
regimen, Vaccine, https://doi.org/10.1016/j.vaccine.2019.11.005was measured immediately before boost and then all weeks there-
after (week 9 to 15, Fig. 2B). Ag85A specific IFN-ɣ expression signif-
icantly increased in the BCG-Ad85A group one week after boost
(P = 0.022 difference to control group, week 9) declining immedi-
ately after (week 10) to background level. There was no change
in expression detectable in the BCG only and control group. After
intranodal challenge (week 13) IFN-ɣ expression increased both
in the BCG and BCG-Ad85A (P < 0.001 and P < 0.01 respectively).
The graph additionally suggests an increase of IFN-ɣ secretion by
stimulated whole blood cells in the control group (not significant).
However, it is worth mentioning that this is due to one control ani-
mal expressing unusual amounts of Ag85A specific IFN-ɣ, both
weeks after challenge (weeks 13 and 14). Two weeks after chal-
lenge, IFN-ɣ secretion by stimulated whole blood cells declined
rapidly in all groups.
To evaluate humoral responses, an optimised PPD-B and Ag85A
ELISA was used. IgG titres were determined before vaccination and
at weeks 4 and 8 after vaccination, at week 12 after boost and week
14 after challenge (Fig. 2C and D). No increase of PPD-B specific IgG
was detected after vaccination (week 4, Fig. 2C), however, intran-
odal challenge with BCG Tokyo resulted in rising titres in both vac-
cinated groups and to a lesser extent in the control group (week 14,
vaccinates versus controls P < 0.01, Fig. 2C). Ag85A specific IgG
titres remained stable after vaccination but increased strongly
after boosting with Ad85A in the BCG-Ad85A group as measured
in sera at week 12 before challenge (BCG-Ad85A versus BCG only
and controls P < 0.0001, Fig. 2D). Intranodal challenge with BCG
did not alter IgG titres in any of the three groups and titres in
the BCG-Ad85A group stayed significanlty higher compared to
BCG only and controls (P < 0.0001, Fig. 2D).. Whole blood was stimulated with either PPD-B (A) or Ag85A (B) for 16 h before
vigam). Shown is the optical density (OD) at 450 nm of the group mean ± SEM after
gG against either PPD-B (C) or Ag85A (D) was determined in ex vivo serum. Controls
NOVA with Tukey’s multiple comparison. Controls versus BCG-Ad85A and BCG only
rsus BCG-Ad85A at week nine **P = 0.002, Controls at week 13 compared to week 12
d85A at week 13 compared to week 12 **P < 0.001 and *P < 0.01 respectively (B);
BCG only and control group at week 12 and 14 ****P < 0.0001 (D).
ivity of the bovine BCG challenge model using a prime boost Ad85A vaccine
L. Biffar et al. / Vaccine xxx (xxxx) xxx 53.2. BCG vaccination alone, and in combination with an Ad85A boost,
increased protection against intranodal challenge significantly over
unvaccinated controls
In the bovine BCG challenge model improved protection is
defined as the ability of animals to induce more effective clearance
of BCG from the injected prescapular lymph node compared to
unvaccinated animals. In this study, vaccination with BCG or prime
boost with BCG-Ad85A resulted in significantly lower numbers of
CFU recovered from lymph nodes compared to control animals
(One-way ANOVA with Tukey’s multiple comparison test,
***P = 0.0001; ****P < 0.0001, mean difference log 1.121 and 0.99,
Fig. 3A). There was no significant difference detectable between
the two different vaccination regimens. In addition to the conven-
tional method of plating out lymph node macerate on solid media
(Fig. 3A) CFUs were determined using BD BACTECTM MGITTM liquid
culture, which provided results up to 4 weeks earlier. CFUs mea-
sured by liquid culture were congruent with the results obtained
by plating on solid media (Pearson r = 0.94; p < 0.0001, Fig. 3B).
Additionally, we investigated dissemination of BCGwithin the lym-
phatic system by measuring bacterial load in the popliteal and sub-
mandibular lymph nodes, hypothesising that there would be more
dissemination in unprotected and control animals compared to pro-
tected animals. BCG Tokyo was detected in popliteal and sub-
mandibular lymph nodes of 3 out of 8 controls and in none of the
vaccinated animals.
3.3. Possible predictors of protection
A major limitation in developing new vaccines against bovine
and human TB is the lack of predictors of protection. In this work
samples were analysed for four possible predictors of protection
in protected and unprotected animals: Antigen specific memory
response measured by cultured IFN-ɣ ELISPOT, differential gene
expression of IL-22, IL-17 and IFN-ɣ in PBMC, intracellular IL-2
and IFN-ɣ expression by CD4+ memory cells and IgG antibody titres
in ex vivo serum. Protected animals were defined as BCG vaccinates
with CFU counts lower than the animal presenting the lowest CFU
counts in the unvaccinated control group and all BCG vaccinated
animals with CFU counts equal to or higher than those animals that
were defined as unprotected. According to this criterium 6 animals
were unprotected, 4 animals from the BCG group and 2 animals
from the BCG-Ad85A group, and all the remaining vaccinated
animals were protected (Fig. 3A).Fig. 3. Level of protection determined by CFU counts in macerate of prescapular lymph n
colonies 6 weeks later. Animals were divided into protected and unprotected, defining a
protected and all animals equal or above as unprotected (red line). *** P = 0.0001; **** P
liquid culture of one in ten diluted macerate was performed using the BD BACTECTM MG
counts on solid media, Pearson R = 0.94; P < 0.0001 (B). (For interpretation of the refere
article.)
Please cite this article as: L. Biffar, L. Blunt, W. Atkins et al., Evaluating the sensit
regimen, Vaccine, https://doi.org/10.1016/j.vaccine.2019.11.005Memory response measured by cultured ELISPOT. Differences
in memory response, measured through antigen specific IFN-ɣ
expression by individual T cells before challenge, have previously
been shown to correlate with protection in pathogenic M. bovis
challenge experiments [12]. Here, we investigated whether this
was also the case in the BCG challenge model. Analysing samples
taken 10 weeks after initial vaccination and 2 weeks after boost
of the BCG-Ad85A group a significant difference in numbers of
antigen specific T cells between the protected group and the con-
trol group, both against PPD-B and Ag85A (PPD-B P = 0.0047,
Ag85A P = 0.0003) but not compared to the unprotected group
(Fig. 4A) was measured.
Antigen specific gene expression.We further analysed antigen
specific IFN-ɣ, IL-17 and IL-22 expression in PBMC, taken 10 weeks
after vaccination and 2 weeks after boost, of all unprotected ani-
mals, six randomly chosen protected animals and four control ani-
mals. There was no significant difference in expression for any of
the three genes evaluated, independent of the antigen used. How-
ever, there was a clear trend for control animals and unprotected
animals to express less antigen specific IFN-ɣ (Fig. 4B and C).
IgG ELISA. Additionally humoral responses were evaluated for
possible differences in IgG titres between protected and unpro-
tected animals (Fig. 4D and E). Antigen specific IgG concentration
did not increase over background levels (week 0) prior to boost
and challenge. After challenge, however, PPD-B specific IgG levels
increased in all three groups, albeit to a much lesser extent in
the control group (Fig. 4D). An increase in Ag85A specific IgG
was detected in sera of all animals of the BCG-Ad85A group after
boost, independent of their protection status. IgG levels did not
change after challenge (Fig. 4E).
CD4 T cell central and effector memory response. We sought
to investigate if there were differences in central and effector
memory reponses in protected compared to unprotected animals.
To do so we initially measured antigen specific intracellular IFN-
ɣ and IL-2 expression in stimulated and unstimulated PBMC in
the four most protected and four unprotected animals from the
BCG only group and four randomly chosen control animals before
and after challenge (week 10 and 14 respectively, see Fig. 3A). An
examplatory gating strategy is provided in supplementary material
Fig. 2. We compared percentages of total CD4+ IFN-ɣ, IL-2 single
and double producers (Fig. 5A and D) and analysed IFN-ɣ and IL-
2 expression by effector CD45RO+CD62Llo and central memory
cells CD45RO+CD62Lhi (Fig. 5B, C, E and F). Two unprotected ani-
mals produced very high amounts of IL-2 and IFN-ɣ both beforeodes. Neat lymph node macerate was plated on 7H11 agar plates and examined for
ll animals with CFUs lower than the control animal with the lowest CFU counts as
< 0.0001, one-way ANOVA with Tukey’s multiple comparison test (A). Additionally,
ITTM system. Time to positivity (TTP) of liquid culture inversely correlated with CFU
nces to colour in this figure legend, the reader is referred to the web version of this
ivity of the bovine BCG challenge model using a prime boost Ad85A vaccine
Fig. 4. Predictors of protection. Cultured ELISPOT, RT-qPCR and serum ELISA were performed as described in material and methods using either rAg85A or PPD-B as the
stimulating antigen and PWM as a positive control in the ELISPOT. For the ELISPOT all animals were analysed and spot forming units were calculated according to
Vordermeier et al. 2009 and are presented as log10SFU/106 cells. Two-way-ANOVA with Tukey’s multiple comparison test *** P = 0.0003, ** P = 0.0047 (A). Differential gene
expression was compared between 4 control animals, 6 unprotected (due to alignment of data points it may appear that there are only 5 unprotected animals in B and C) and
7 randomly chosen protected animals (B and C). Serum ELISA was performed for all animals. Controls (d), unprotected ( ), protected ( ).
6 L. Biffar et al. / Vaccine xxx (xxxx) xxxand after challenge. There was a trend for vaccinated animals, both
protected and unprotected, to have more IFN-ɣ and IL-2 single pro-
ducer and especially more double producers. CD8 and ɣd T cells did
not express any IL-2 and very little IFN-ɣ, with no difference
between the three groups (data not shown). In general, there was
an increase of IFN-ɣ and IL-2 single and double producers within
the CD4+, TCM and TEM cell populations after challenge (week
14) compared to before challenge (week 10) with no significant
difference between protected, unprotected and control animals.
Given there was no significant difference between the most and
least protected animals we did not proceed with testing further
animals.4. Discussion
The ability of a vaccine to confer protection is often determined
through challenge studies with the pathogen of interest. In the casePlease cite this article as: L. Biffar, L. Blunt, W. Atkins et al., Evaluating the sensit
regimen, Vaccine, https://doi.org/10.1016/j.vaccine.2019.11.005of humanTB, there is no experimental model for M. tuberculosis
human challenge studies, however, challenge models to evalute
the efficacy of vaccine candidates prior to evaluation in clinical tri-
als using BCG as a surrogate challenge are being evaluated [18–20].
In cattle, unlike in humans, it is possible to carry out challenge
studies with M. bovis [21]. Those studies, however, are very costly
due to their long duration and necessity of housing animals in BSL3
facilities which are not widely available. Methods allowing for an
initial screening of vaccine candidates would help in the selection
of the most promising candidates to be tested inM. bovis challenge
studies and as a consequence reduce the number of vaccine evalu-
ation trials. The recently developed bovine BCG challenge model
would offer a fast and comparatively cheap way to pre-select vac-
cine candidates. The aim of this work was to further determine the
potential utility of this model as a gating strategy for the selection
of vaccine candidates prior to evaluation in M. bovis challenge
experiments. No statistically significant difference in bacterial
counts were found between the BCG-vaccinated and BCG-Ad85Aivity of the bovine BCG challenge model using a prime boost Ad85A vaccine
Fig. 5. Antigen specific memory response measured in CD4+ and effector CD45RO+CD62Llo and central CD45RO+CD62Lhi memory cells. IFN-ɣ and IL-2 expression was
measured in the four most protected, four unprotected animals from the BCG only group and four randomly chosen control animals. A and D show the percentage of CD4+
cells producing either IFN-ɣ or IFN-ɣ and IL-2. B and E show percentage of CD45RO+CD62Lhi IFN-ɣ/IL-2 single and double producers, C and F show percentage of
CD45RO+CD62Llo IFN-ɣ/IL-2 single and double producers. Results are presented as stimulated minus unstimulated PBMC. *P < 0.05, **P < 0.01, ***P < 0.001. D – F dotted line at
1%. Controls (d), unprotected ( ), protected ( ).
L. Biffar et al. / Vaccine xxx (xxxx) xxx 7vaccinated and boosted groups. The bacterial load in prescapular
lymph nodes of both vaccinated groups was reduced by around 1
log CFU/ml compared to animals in the control group. Whilst this
may be considered a narrowwindow for the distinction of the level
of protection conferred by two different vaccination regimens, it is
important to highlight a few points. BCG-Ad85A was shown to con-
fer a significantly greater degree of protection than BCG alone in a
vaccination and M. bovis challenge trial at the histopathological
[14] but not gross pathology level [12,14]. The BCG challenge
model cannot evaluate pathology to the same degree as possibile
in M. bovis challenge experiments since BCG being less virulent
than M. bovis does not induce comparable immunopathology and
therefore can only provide indicators of the ability of individuals
to contain/kill mycobacteria. Dividing animals into protected and
unprotected, as described above, indicated that in the BCG group
there were four unprotected animals, out of a total of 13 animals
in the group, whilst in the BCG-Ad85A group there were two
unprotected animals, out of a total of 14 animals. So even though
there was no significant difference detectable between the two
vaccination regimens, the data suggests a slightly better protection
of BCG-AD85A compared to BCG alone. There is a need to develop
vaccines that confer substantially better protection than the cur-
rently experimentally used BCG and the BCG challenge model
may be able to show these larger differences.
Previously, dissemination of BCG from the injected prescapular
lymph node to popliteal and submandibular lymph nodes was
measured as an indicator of the ability of the individual to con-
tain/kill mycobacteria [10]. Similar to previous studies, BCG was
found in submandibular and popliteal lymph nodes of a few con-
trol animals but not in lymph nodes other than the injected lymph
node in the vaccinated groups.
Transcription of IFN-ɣ in antigen stimulated PBMC and memory
responses, as measured by cultured IFN-ɣ ELISPOT, have been
shown to correlate with protection in M. bovis challenge experi-
ments [12]. Therefore we sought to analyse if this was also the casePlease cite this article as: L. Biffar, L. Blunt, W. Atkins et al., Evaluating the sensit
regimen, Vaccine, https://doi.org/10.1016/j.vaccine.2019.11.005in the BCG challenge model. For this analysis, animals were divided
into protected and unprotected, as described above, resulting in
two out of 14 unprotected in the BCG-Ad85A and four out of 13
unprotected in the BCG only group. In both, cultured ELISPOT
and quantitative PCR, a trend for less IFN-ɣ expression by T cells
in the unprotected group compared to the protected group, similar
to the control group was measured in samples taken 10 weeks
after initial vaccination and 2 weeks after animals of the BCG-
Ad85A group had received the boost. Even though there was no
significant difference in IFN-ɣ expression between protected and
unprotected animals in the cultured Elispot, protected but not
unprotected, animals produced significantly larger amounts of
IFN-ɣ compared to controls. We additionally analysed whether
there were differences in numbers of central and effector memory
T cells and the amount of IFN-ɣ/IL-2 they produced. Initially we
analysed our most protected and least protected animals with
the idea to include all animals should there be significant differ-
ences between the most protected and unprotected animals. How-
ever, the data did not suggest that we would find more differences.
In summary there is a trend for protected animals to produce more
IFN-ɣ as measured in all our assays. The analysis for predictors of
protection is limited by the number of animals that are classified
as protected and unprotected, in this study the proportion of pro-
tected animals was larger than anticipated from previous studies
and therefore, future studies may require a larger number of ani-
mals to enable identification of significant predictors of protection.
Experiments carried out in the 1980s had indicated that anti-
bodies were not necessarily involved in the protection against
mycobacteria. However, there was a degree of disagreement
between different experiments [22]. More recent experiments
[23] have indicated that antibodies could play a role in protection
against mycobacteria and therefore, it was of interest to analyse
the extent to which the different vaccination regimens induced
humoral response in order to determine whether the induction
of antibodies could be used as a marker of protection. We didivity of the bovine BCG challenge model using a prime boost Ad85A vaccine
8 L. Biffar et al. / Vaccine xxx (xxxx) xxxnot observe any differences in the induction of humoral responses
against PPD-B between the two vaccination regimens. Although
antibodies to Ag85A were induced by the BCG-Ad85A vaccination
and boosting regimen, no correlation between level of antibodies
and degree of protection were observed. Further experiments will
need to be carried out to determine the extent to which this obser-
vation can be applied to the bovine TB model.
In summary the bovine BCG challenge model offers a faster,
cheaper way to evaluate newly developed vaccines against bovine
tuberculosis, in particular to gate out vaccines that are less effec-
tive than BCG, and also reduces the severity of challenge compared
to M. bovis challenge. Additionally, protection in the current BCG
challenge experiments correlated with predictors of protection
found inM. bovis challenge experiments and might thus be a useful
model for research on biomarkers of protection.
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